LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced ...

There is currently no cure for polycythemia vera (PV), but researchers are looking at new treatments that may help better manage and control the progression of the condition. Polycythemia vera (PV) is ...

Polycythemia vera (PV) is a rare blood cancer causing the bone marrow to make too many blood cells. Treatment usually starts with phlebotomy and may continue with medications. If one treatment isn’t ...

At four-year follow up, treatment with givinostat, a histone-deacetylase inhibitor, continued to be safe and effective with no serious or life-threatening side effects. Patients with polycythemia vera ...

A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. Polycythemia vera falls under the ...

Besremi is a monopegylated, long-acting interferon, which exhibits its cellular effects in the bone marrow in polycythemia vera. The Food and Drug Administration (FDA) has approved Besremi ® ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: My husband (age 71) received a diagnosis of polycythemia ...

Patients diagnosed with polycythemia vera currently have more specialized treatment options that may lead to improved responses to therapy, an expert said. Dr. Jamile M. Shammo, professor of medicine ...

Polycythemia vera (PV) therapy should aim to identify cardiovascular risk factors, according to one review. Diagnosis and management of cardiovascular (CV) events including stroke, heart attacks, and ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in ...

Few cases have documented how myeloproliferative neoplasms, such as polycythemia vera, progress to pure erythroid leukemia, with just 5 such cases reported between 1952 and 1962. Adding to the limited ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...